Loading...
Loading...
CSTL| Name | Value |
|---|---|
| Revenues | 86.2M |
| Cost of Revenue | 20.1M |
| Gross Profit | 66.1M |
| Operating Expense | 70.3M |
| Operating I/L | -4.3M |
| Other Income/Expense | 4.1M |
| Interest Income | 2.9M |
| Pretax | -0.1M |
| Income Tax Expense | -4.7M |
| Net Income/Loss | 4.5M |
Castle Biosciences, Inc. is a commercial-stage diagnostics company specializing in providing diagnostic and prognostic testing services for dermatological cancers. The company's primary revenue-generating products include DecisionDx-Melanoma, a multi-gene expression profile (GEP) test for identifying the risk of metastasis in invasive cutaneous melanoma patients, DecisionDx-UM test for predicting the risk of metastasis in patients with uveal melanoma, DecisionDx-SCC for predicting individual risk of squamous cell carcinoma metastasis, and DecisionDx DiffDx-Melanoma and myPath Melanoma for diagnosing suspicious pigmented lesions. These tests are offered through physicians and their patients, forming the core of the company's revenue stream.
